Dr Meredith McKean speaks to ecancer about the 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial that she presented at ASCO 2024.

The trial evaluated the use of the individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma.

She reports that this 3-year update demonstrated a relapse-free survival benefit, which is even increasing with time, and also a nearly 50% improvement in recurrence versus pembrolizumab monotherapy.

Dr McKean also details a sustained improvement in distant metastasis-free survival showing that patients are being prevented from developing metastatic disease in areas that are not local.